...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Scandinavian journal of clinical and laboratory investigation. >Soluble receptor for advanced glycation end products predicts 28-day mortality in critically ill patients with sepsis
【24h】

Soluble receptor for advanced glycation end products predicts 28-day mortality in critically ill patients with sepsis

机译：晚期糖基化终产物的可溶性受体可预测重症脓毒症患者的28天死亡率

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective. Multiple biomarkers are used to assess sepsis severity and prognosis. Increased levels of the soluble receptor for advanced glycation end products (sRAGE) were previously observed in sepsis but also in end-organ injury without sepsis. We evaluated associations between sRAGE and (i) 28-day mortality, (ii) sepsis severity, and (iii) individual organ failure. Traditional biomarkers procalcitonin (PCT), C-reactive protein (CRP) and lactate served as controls. Methods. sRAGE, PCT, CRP, and lactate levels were observed on days 1 (D1) and 3 (D3) in 54 septic patients. We also assessed the correlation between the biomarkers and acute respiratory distress syndrome (ARDS), acute kidney injury (AKI) and acute heart failure. Results. There were 38 survivors and 16 non-survivors. On D1, non-survivors had higher sRAGE levels than survivors (p = 0.027). On D3, sRAGE further increased only in non-survivors (p < 0.0001) but remained unchanged in survivors. Unadjusted odds ratio (OR) for 28-day mortality was 8.2 (95% CI: 1.02-60.64) for sRAGE, p = 0.048. Receiver operating characteristic analysis determined strong correlation with outcome on D3 (AUC = 0.906, p < 0.001), superior to other studied biomarkers. sRAGE correlated with sepsis severity (p < 0.00001). sRAGE showed a significant positive correlation with PCT and CRP on D3. In patients without ARDS, sRAGE was significantly higher in non-survivors (p < 0.0001) on D3. Conclusion. Increased sRAGE was associated with 28-day mortality in patients with sepsis, and was superior compared to PCT, CRP and lactate. sRAGE correlated with sepsis severity. sRAGE was increased in patients with individual organ failure. sRAGE could be used as an early biomarker in prognostication of outcome in septic patients.
机译：目的。多种生物标志物用于评估败血症严重程度和预后。先前在脓毒症中观察到晚期糖基化终产物（sRAGE）的可溶性受体水平增加，但在没有脓毒症的终末器官损伤中也观察到。我们评估了sRAGE与（i）28天死亡率，（ii）败血症严重程度和（iii）单个器官衰竭之间的关联。传统的生物标志物降钙素（PCT），C反应蛋白（CRP）和乳酸盐作为对照。方法。在54名败血症患者的第1天（D1）和第3天（D3）观察到sRAGE，PCT，CRP和乳酸水平。我们还评估了生物标志物与急性呼吸窘迫综合征（ARDS），急性肾损伤（AKI）和急性心力衰竭之间的相关性。结果。有38位幸存者和16位非幸存者。在D1上，非幸存者的sRAGE水平高于幸存者（p = 0.027）。在第3天，sRAGE仅在非幸存者中进一步增加（p <0.0001），而在幸存者中保持不变。 sRAGE的28天死亡率的未调整优势比（OR）为8.2（95％CI：1.02-60.64），p = 0.048。接受者的操作特征分析确定与D3的结果密切相关（AUC = 0.906，p <0.001），优于其他研究的生物标志物。 sRAGE与脓毒症严重程度相关（p <0.00001）。 sRAGE与D3上的PCT和CRP呈显着正相关。在没有ARDS的患者中，D3期非存活者的sRAGE显着更高（p <0.0001）。结论。败血症患者的sRAGE增加与28天死亡率相关，并且优于PCT，CRP和乳酸。 sRAGE与败血症的严重程度有关。个体器官衰竭患者的sRAGE增加。 sRAGE可作为败血病患者预后的早期生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号